BigHat Biosciences: Series C

The business

BigHat combines machine learning with synthetic biology to design and optimize antibody candidates across multiple properties. Its platform also generates experimental data for rapid protein design, linking computational models with laboratory work. The Series C is intended to advance the company’s clinical-stage therapeutics pipeline and expand its data platform for antibody engineering.

Funding history

Sep 24, 2026Series C · This round$75M

Sources

BigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design - BioSpacebiospace.com · Sep 24, 2026

Similar rounds

All Biotech rounds →

WhiteLab Genomics

WhiteLab Genomics uses AI to design genetic medicines and develop bio-assets for cell, RNA and DNA therapies.

$26MSeries B · Oct 6, 2026

Autopoiesis Sciences

Autopoiesis Sciences is developing AI research tools that help scientists plan and carry out scientific discovery.

$11MSeed · Oct 6, 2026

Sensible Biotechnologies

A platform for designing and manufacturing naturally modified mRNA medicines.

$47MSeries A · Oct 6, 2026

Aventix

Aventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.

€1.2MPre-seed · Sep 30, 2026

The business

Funding history

Sources

Similar rounds

Related